Drugs / Lactobacillus Fermentum
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05527301 | Jan 2024 → Jan 2026 | — | HEM Pharma Inc. | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| — | NCT04572932 Comparator | May → Dec 2019 | irritable bowel syndrome | Ain Shams University | Completed | No outcome recorded |
| — | NCT00256022 Comparator | Jul → Dec 2007 | — | Melbourne Health | Withdrawn | No outcome recorded |
| — | NCT00256087 Comparator | Jan 2005 → Jan 2010 | — | Melbourne Health | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus Fermentum | “first group was prescribed probiotics (10 billion colony of lactobacillus delbruekii and lactobacillus fermentum) and itopride hcl 50mg three times daily for 4 weeks” NCT04572932 ↗3“The first active treatment group, will receive enteral feeding (with fibre) plus probiotic Lactobacillus fermentum included in the feeding regime.” NCT00256087 ↗ “Two different lactobacillus strains will be assessed in the study: Lactobacillus Acidophilus and Lactobacillus Fermentum.” NCT00256022 ↗ |
| Modality | Other / unclassified | “pre-operative prophylactic probiotic Lactobacilli tablets” NCT00256022 ↗ |
| Route | Other | “Two capsules containing Lactobacillus fermentum (10 11 organisms per capsule) will be delivered via the feeding tube 12 hourly.” NCT00256087 ↗ |